Target intelligence / Profile preview

SMG6 nonsense mediated mRNA decay factor (SMG6)

Target
SMG6
Molecular classification
Endonuclease, RNA-binding protein, Telomerase-associated factor, PIN domain protein, mRNA surveillance factor
01

Overview

SMG6 is a conserved mammalian endonuclease and RNA surveillance factor that regulates gene expression and genome stability through two key pathways: nonsense-mediated mRNA decay and telomere maintenance[1][2][3][4][5][7]. As an endonuclease, SMG6 cleaves defective mRNAs containing premature stop codons, preventing expression of truncated proteins. It is also a telomerase-associated factor (EST1A), essential for proper telomere replication and chromosome stability—its disruption leads to telomere shortening and cell cycle defects. SMG6 is broadly expressed and contributes to embryonic stem cell differentiation and neurogenesis, with important roles in cancer and cardiovascular disease[3][5][7]. Note on SMG6-AS1: There is currently no high-confidence data describing "SMG6 antisense RNA 1" (SMG6-AS1) as a validated molecular target, therapeutic or otherwise, nor is it listed in major gene/protein databases. It is likely a predicted lncRNA or antisense transcript whose function remains to be fully characterized. The canonical gene/protein target in this region is SMG6.

Other names
SMG6C17orf31EST1-like protein AEST1AEver shorter telomeres 1AKIAA0732
02

Mechanism of action

Not applicable; no directly interacting drugs reported. SMG6 itself functions via endonucleolytic cleavage of mRNAs containing premature stop codons by the PIN domain, and interaction with telomerase complexes to maintain telomere ends.

03

Biological functions

Nonsense-mediated mRNA decay (NMD)RNA quality controlTelomere maintenanceRegulation of embryonic stem cell differentiationRegulation of neurogenesisApoptosis (induced by telomere dysfunction)Genome stability
04

Disease associations

Cancer (regulation of telomere length; cell viability impacts)Neurodevelopmental syndromes (defects in neurogenesis)Cardiovascular disease (SNPs associated via GWAS)
05

Safety considerations

Potential induction of apoptosis due to chromosome end fusions by persistent SMG6 activityGlobal impacts on genome stability and cell fate—therapeutic manipulation may lead to cell death or arrest
06

Biomarkers

Genetic risk score including SMG6 SNPs for coronary artery diseaseMethylation status at SMG6 loci associated with disease risk

Beyond the preview

Go deeper on SMG6 nonsense mediated mRNA decay factor (SMG6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SMG6 nonsense mediated mRNA decay factor (SMG6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call